Camiglibose

Camiglibose

SCHEMBL1201508

CO[C@@H]1O[C@H](CN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GAA P10253 9/20 0.50
MGAM O43451 8/20 0.50
SI P14410 3/20 0.46
GBA1 P04062 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
LCT P09848 1/20 0.46
GBA2 Q9HCG7 7/20 0.46
UGCG Q16739 3/20 0.46
AGL P35573 2/20 0.46
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Camiglibose SCHEMBL19510347 1.00 GAA (0.50) GAAMGAMSIGBA1TDP1
Camiglibose SCHEMBL3952283 1.00 GAA (0.50) GAAMGAMSIGBA1TDP1
Camiglibose SCHEMBL2052995 1.00 GAA (0.50) GAAMGAMSIGBA1TDP1
Camiglibose SCHEMBL5186895 1.00 GAA (0.50) GAAMGAMSIGBA1TDP1
Camiglibose SCHEMBL4604473 1.00 GAA (0.50) GAAMGAMSIGBA1TDP1
Camiglibose SCHEMBL758524 1.00 GAA (0.50) GAAMGAMSIGBA1TDP1
Camiglibose SCHEMBL5238483 1.00 GAA (0.50) GAAMGAMSIGBA1TDP1
Camiglibose SCHEMBL614436 1.00 GAA (0.50) GAAMGAMSIGBA1TDP1
Camiglibose SCHEMBL6794338 1.00 GAA (0.50) GAAMGAMSIGBA1TDP1
Camiglibose SCHEMBL37446 0.99 GAA (0.49) GAAMGAMSIGBA1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877717-B2 Anti-diabetic extract of rooibos ZADEC APS (DK) 2014-11-04 US disclosed
US-20120251643-A1 ANTI-DIABETIC EXTRACT OF HONEYBUSH ZADEC APS (DK) 2012-10-04 US disclosed
US-20110275579-A1 ANTI-DIABETIC EXTRACT OF ROOIBOS ZADEC APS (DK) 2011-11-10 US disclosed
EP-2368560-A1 An anti-diabetic extract of rooibos Zadec ApS (DK) 2011-09-28 EP disclosed
US-20110045108-A1 ANTI-DIABETIC EXTRACT OF HONEYBUSH ZADEC APS (DK) 2011-02-24 US disclosed
EP-2120980-A1 AN ANTI-DIABETIC EXTRACT OF ROOIBOS Zadec APS (DK) 2009-11-25 EP disclosed
EP-2120924-A2 AN ANTI-DIABETIC EXTRACT OF HONEYBUSH Zadec APS (DK) 2009-11-25 EP disclosed
WO-2008110552-A9 AN ANTI-DIABETIC EXTRACT OF HONEYBUSH ZADEC APS (DK) 2008-12-04 WO disclosed
WO-2008110552-A2 AN ANTI-DIABETIC EXTRACT OF HONEYBUSH ZADEC APS (DK) 2008-09-18 WO disclosed
WO-2008110551-A1 AN ANTI-DIABETIC EXTRACT OF ROOIBOS ZADEC APS (DK) 2008-09-18 WO disclosed
US-7416744-B2 Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use CONOPCO, INC. (US) 2008-08-26 US disclosed
US-20070173548-A1 Malonamic acids and derivatives thereof as thyroid receptor ligands CHIANG YUAN-CHING P 2007-07-26 US disclosed
US-20060159779-A1 Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use PHYTOPHARM PLC 2006-07-20 US disclosed
US-7033616-B2 Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use PHYTOPHARM PLC (GB) 2006-04-25 US disclosed
US-20020146468-A1 Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use CONOPCO, INC., D/B/A UNILEVER 2002-10-10 US disclosed
EP-1166792-A2 Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use PHYTOPHARM PLC (GB) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275579-A1 ANTI-DIABETIC EXTRACT OF ROOIBOS RDX, RARS2, RRP12 GAA 1097/4885MGAM 710/4885SI 150/4885
US-20020146468-A1 Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use GANAB, NACA, DPP7 GAA 84/4885MGAM 55/4885SI 487/4885
US-20110045108-A1 ANTI-DIABETIC EXTRACT OF HONEYBUSH IAPP, DPP4, DPP3 GAA 480/4885MGAM 24/4885SI 579/4885
US-20060159779-A1 Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use GANAB, HDAC7, NACA GAA 102/4885MGAM 55/4885SI 288/4885
US-20120251643-A1 ANTI-DIABETIC EXTRACT OF HONEYBUSH IAPP, DPP4, DPP3 GAA 480/4885MGAM 24/4885SI 579/4885
US-20070173548-A1 Malonamic acids and derivatives thereof as thyroid receptor ligands THRA, MC1R, TSHR GAA 521/4885MGAM 1056/4885SI 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.